Driehaus Capital Management LLC Ascendis Pharma A/S Transaction History

Driehaus Capital Management LLC

$9.17 Billion
Q1 2025

A detailed history of Driehaus Capital Management LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Driehaus Capital Management LLC holds 151,829 shares of ASND stock, worth $24.2 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

151,829

Previous 88,496 71.57%

Holding current value

$24.2 Million

Previous $12.2 Million 94.24%

% of portfolio

0.26%

Previous 0.12%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$119.49 - $168.84 $7.57 Million - $10.7 Million	63,333 Added 71.57%	151,829 $23.7 Million
Q4 2024 Feb 14, 2025	SELL	$122.0 - $146.6 $3.15 Million - $3.78 Million	-25,818 Reduced 22.59%	88,496 $12.2 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $3.72 Million - $5.05 Million	32,918 Added 40.44%	114,314 $17.1 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $2.29 Million - $2.91 Million	-18,924 Reduced 18.86%	81,396 $11.1 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $12.4 Million - $16 Million	100,320 New	100,320 $15.2 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $734 - $887	7 Added 0.0%	180,234 $19.3 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $5.66 Million - $7.51 Million	56,887 Added 46.12%	180,227 $22 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $1.19 Million - $1.56 Million	-14,170 Reduced 10.3%	123,340 $12.7 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $639,084 - $962,637	8,185 Added 6.33%	137,510 $12.8 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $4.91 Million - $6.53 Million	48,079 Added 59.18%	129,325 $15.2 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $12,582 - $16,796	99 Added 0.12%	81,246 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $2.81 Million - $4.41 Million	24,914 Added 44.3%	81,147 $12.9 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $467,507 - $558,494	3,844 Added 7.34%	56,233 $7.4 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $16.5 Million - $22.9 Million	-131,931 Reduced 71.58%	52,389 $6.75 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $2.91 Million - $3.51 Million	19,219 Added 11.64%	184,320 $30.7 Million
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $2.85 Million - $3.27 Million	-21,206 Reduced 11.38%	165,101 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $2.34 Million - $3.29 Million	21,063 Added 12.75%	186,307 $27.6 Million
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $953,802 - $1.43 Million	9,832 Added 6.33%	165,244 $18.6 Million
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $1.17 Million - $1.78 Million	12,807 Added 8.98%	155,412 $21.6 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $69,550 - $86,321	-726 Reduced 0.51%	142,605 $13.7 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $2.95 Million - $3.64 Million	-27,534 Reduced 16.11%	143,331 $16.5 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $9.04 Million - $18.9 Million	145,451 Added 572.33%	170,865 $20.1 Million
Q4 2018 Feb 14, 2019	SELL	$55.16 - $69.67 $1.35 Million - $1.71 Million	-24,492 Reduced 49.08%	25,414 $1.59 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $657,660 - $786,675	10,313 Added 26.05%	49,906 $3.54 Million
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $552,009 - $696,917	-9,428 Reduced 19.23%	39,593 $2.63 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $1.91 Million - $3.34 Million	49,021 New	49,021 $3.21 Million
Q4 2017 Feb 14, 2018	SELL	$31.98 - $40.38 $3.18 Million - $4.01 Million	-99,328 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $2.67 Million - $3.69 Million	99,328	99,328 $3.6 Million

Others Institutions Holding ASND

# of Institutions

270

Shares Held

61.9M

Call Options Held

151K

Put Options Held

226K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.89B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.

Account

Driehaus Capital Management LLC Ascendis Pharma A/S Transaction History